News Column

Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update

May 20, 2014

By a News Reporter-Staff News Editor at Cancer Weekly -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, announced financial results for the first quarter ended March 31, 2014 and provided an update on its development program for ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III program for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer (see also Celsion Corporation).

"Since the beginning of the year, we have been focused on executing our clinical strategy for ThermoDox, and have made significant progress this quarter toward launching a well-designed, global and robust Phase 3 program for ThermoDox in primary liver cancer," said Michael Tardugno, Celsion's President and Chief Executive Officer. "The survival data emerging from our HEAT Study underscore the potential of ThermoDox in combination with an optimized radiofrequency ablation regimen. We worked closely with statisticians, regulators and leading experts in liver cancer to design our Phase III OPTIMA Study, which we believe establishes a clear path to approval. We also continue to work to identify strategic opportunities that provide synergistic and complementary assets supporting additional growth opportunities for our shareholders."

Keywords for this news article include: Cancer, Oncology, Celsion Corporation, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Cancer Weekly

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters